Breakthroughs in Breast Cancer – Insights from ESMO 2024.
White Paper based on late-breaking abstracts presented in Barcelona.
Early-stage breast cancer, among the most frequently diagnosed cancers globally, was a key focus at this year’s ESMO conference, with sessions dedicated to advancing novel therapeutic strategies, improving personalized treatment approaches, and tackling survivorship challenges.
“Breakthroughs in Breast Cancer” explores the breakthroughs presented, focusing on therapeutic advancements in early-stage breast cancer, such as targeted therapies, immunotherapy combinations, and precision radiotherapy. It emphasizes the critical role of real-world evidence (RWE) in addressing persistent challenges, including treatment resistance, toxicity management, and recurrence.
OXON, with its expertise in global RW data collection (chart review and prospective and registry studies) and secondary data observational studies and trials, together with world-leading statisticians and oncologists is ideally positioned to address these emerging needs in breast cancer treatment across Europe, USA, and Asia, to support clinical development, market access, and safety.
To download the white paper, please complete the following form.